Contributions
Abstract: P937
Type: Poster
Abstract Category: Clinical aspects of MS - 11 Comorbidity
Introduction: Coexistence of other autoimmune diseases is well recognized in patients with multiple sclerosis (MS) that suggests autoimmune dysregulation in at least a subset of patients. However, the effect of this comorbidity on the clinical course of MS is not clear.
Aim: In our study, we aimed to compare the clinical progression of MS patients with and without comorbid autoimmune diseases.
Methods: We recruited all MS patients with at least one-year follow-up in our study. Patients were divided into two groups according to presence (Group I) or absence (Group II) of other autoimmune disorders. We collected demographic and clinical data including age at disease onset, EDSS 3, and EDSS 6. Time to reach EDSS 3 and EDSS 6 were compared using log rank test and Cox logistic regression analysis.
Results: Group I consisted of patients with uveitis (n=42) psoriasis (n=10), rheumatoid arthritis (n=6), and ankylosing spondylitis (n=5). Group II consisted of 676 patients (471 female, 205 male). There was no difference between both groups in terms of age, gender, age at diagnosis, time to treatment onset, subtype of MS, and follow-up duration. Additionally, we did not observe any difference between both groups in terms of age at onset (29.4 vs. 29.4; p=0.99), time to reach EDSS 3 (9.7 vs. 7.8 years; p=0.026), and EDSS 6 (10.8 vs. 9.5 years; p=0.15), age at EDSS 3 (39.1 vs. 37.2; p=0.25), and EDSS 6 (40.3 vs. 38.9; p=0.42), and progression index (0.34 vs. 0.41; p=0.21). Univariate logistic regression analysis also showed that coexistent autoimmune disease does not affect EDSS progression in MS patients.
Discussion: Our study clearly showed that comorbid autoimmune diseases do not have an unfavorable prognostic effect on the clinical course in patients with MS. Despite systemic autoimmunity, patients do not seem to exhibit an enhanced progression rate. However, we still believe that search for other autoimmune disorders is important since their presence may change the management of patients.
Disclosure:
Tuncay Gündüz: Nothing to Disclose
Ahmed Serkan Emekli: Nothing to Disclose
Murat Kürtüncü: Nothing to Disclose
Mefküre Eraksoy: Nothing to Disclose
Abstract: P937
Type: Poster
Abstract Category: Clinical aspects of MS - 11 Comorbidity
Introduction: Coexistence of other autoimmune diseases is well recognized in patients with multiple sclerosis (MS) that suggests autoimmune dysregulation in at least a subset of patients. However, the effect of this comorbidity on the clinical course of MS is not clear.
Aim: In our study, we aimed to compare the clinical progression of MS patients with and without comorbid autoimmune diseases.
Methods: We recruited all MS patients with at least one-year follow-up in our study. Patients were divided into two groups according to presence (Group I) or absence (Group II) of other autoimmune disorders. We collected demographic and clinical data including age at disease onset, EDSS 3, and EDSS 6. Time to reach EDSS 3 and EDSS 6 were compared using log rank test and Cox logistic regression analysis.
Results: Group I consisted of patients with uveitis (n=42) psoriasis (n=10), rheumatoid arthritis (n=6), and ankylosing spondylitis (n=5). Group II consisted of 676 patients (471 female, 205 male). There was no difference between both groups in terms of age, gender, age at diagnosis, time to treatment onset, subtype of MS, and follow-up duration. Additionally, we did not observe any difference between both groups in terms of age at onset (29.4 vs. 29.4; p=0.99), time to reach EDSS 3 (9.7 vs. 7.8 years; p=0.026), and EDSS 6 (10.8 vs. 9.5 years; p=0.15), age at EDSS 3 (39.1 vs. 37.2; p=0.25), and EDSS 6 (40.3 vs. 38.9; p=0.42), and progression index (0.34 vs. 0.41; p=0.21). Univariate logistic regression analysis also showed that coexistent autoimmune disease does not affect EDSS progression in MS patients.
Discussion: Our study clearly showed that comorbid autoimmune diseases do not have an unfavorable prognostic effect on the clinical course in patients with MS. Despite systemic autoimmunity, patients do not seem to exhibit an enhanced progression rate. However, we still believe that search for other autoimmune disorders is important since their presence may change the management of patients.
Disclosure:
Tuncay Gündüz: Nothing to Disclose
Ahmed Serkan Emekli: Nothing to Disclose
Murat Kürtüncü: Nothing to Disclose
Mefküre Eraksoy: Nothing to Disclose